
FDA Delivers CRL for Longer Dosage Intervals in Aflibercept for DME, Wet AMD
Key Takeaways
- High-dose aflibercept offers extended dosing intervals for DME and wet AMD, with sustained visual and anatomical improvements.
- The PULSAR and PHOTON trials showed efficacy in maintaining vision gains with fewer injections over extended periods.
The complete response letter (CRL) specifies that the current dosage duration of aflibercept is still safe but extending the duration is not approved.
High-dosage aflibercept (Eylea HD; Regeneron) can not be taken every 24 weeks for diabetic macular edema (DME) or wet age-related macular degeneration (AMD) after the FDA delivered a complete response letter (CRL) to Regeneron on
High-dose aflibercept can be used in DME, wet AMD, and diabetic retinopathy in an 8-mg dose, which is 6 mg more than the original dose. The treatment can be taken at 8 mg every 4 weeks for 3 months and then 8 mg every 8 to 16 weeks for wet AMD or DME. The treatment offered fewer injections than the regular dose and was the first and only treatment to offer up to 16 weeks between injections. This biologics license application sought to build on that approval to offer up to 24 weeks between injections with noninferior results.
This application was based on a
There were 375 patients who completed 2 years of treatment and participated in the extension study that was conducted for 60 weeks, totaling 3 years. All patients were randomly assigned to either 3 or 4 months between doses after taking their first 3 doses monthly. All patients could change their dosing interval based on criteria. The study found that 88% of the patients were able to have at least 3 months between doses, 60% kept an interval of at least 4 months, 40% extended to at least 5 months, and 24% extended to 6 months. All of their visual gains and anatomical improvements achieved through 2 years lasted through the extension study.
Patients who switched from a regular 2-mg dose of aflibercept of taken every 2 months to a high dose of aflibercept were included in the study after 2 years. The 186 patients saw all improvements maintained through the last year of treatment, with 79% of patients having a dosing interval of at least 3 months and 43% having a dosing interval of at least 4 months. Adverse events related to treatment occurred in at least 4% of the participants, with reduction of visual acuity, vitreous floaters, retinal hemorrhage, cataracts, and an increase in ocular pressure all recorded.
The
Regeneron is looking to evaluate the decision made by the FDA in order to address any issues that the FDA had with the application in order to move forward, as the CRL did not specify any issues with aflibercept in its current dosing intervals. High-dosage aflibercept will continue to be available to patients with AMD and DME in its current form.
References
- Regeneron provides update on Eylea HD (aflibercept) injection 8 mg supplemental biologics license application. News release. Regeneron; April 18, 2025. Accessed April 21, 2025.
https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-eylea-hdr-aflibercept-injection-8-mg - Jeremias S. FDA approves higher-dose version of aflibercept. AJMC®. August 31, 2023. Accessed April 18, 2025.
https://www.ajmc.com/view/fda-approves-higher-dose-version-of-aflibercept - Three-year results for Eylea HD (aflibercept) injection 8 mg in patients with wet age-related macular degeneration demonstrate continued durable vision gains and anatomic improvements with extended dosing intervals. News release. Regeneron; February 8, 2025. Accessed April 18, 2025.
https://investor.regeneron.com/news-releases/news-release-details/three-year-results-eylea-hdr-aflibercept-injection-8-mg-patients - Two-year results for aflibercept 8 mg from pivotal PHOTON trial demonstrate durable vision gains at extended dosing intervals in diabetic macular edema. News release. Regeneron; June 27, 2023. Accessed April 18, 2025.
https://investor.regeneron.com/news-releases/news-release-details/two-year-results-aflibercept-8-mg-pivotal-photon-trial
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.